» Articles » PMID: 40034959

Third Liver Resection for Re-recurrent Hepatocellular Carcinoma: Assessment of the Prognostic Factors of Long-term Survival

Overview
Specialty Oncology
Date 2025 Mar 4
PMID 40034959
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: Second hepatic resection is a well-established and effective treatment for recurrent hepatocellular carcinoma (HCC). Despite this, the recurrence rate of HCC remains high. The efficacy of third liver resection for re-recurrent HCC is uncertain, and prognostic factors affecting survival after third hepatectomy have not been comprehensively evaluated. This study aimed to investigate the short- and long-term outcomes of third liver resection for re-recurrent HCC and identify prognostic factors affecting survival.

Patients And Methods: In total, 27 patients who underwent three liver resections for primary, recurrent, and re-recurrent HCC were retrospectively reviewed. The prognostic factors of long-term survival were evaluated using clinical data including those of previous liver resections.

Results: No cases of perioperative mortality after third liver resection for re-recurrent HCC were found. The median overall survival and disease-free survival were 38.3 and 5.8 months, respectively. The 5-year overall survival and disease-free survival rates were 56.8% and 10.9%, respectively. Clinical parameters such as tumor marker level, primary tumor size, and surgical interval of the third liver resection and of the first and second surgeries were significantly associated with long-term survival.

Conclusion: The survival rate of third liver resection for re-recurrent HCC in our study was similar to that reported for second and third hepatectomies in previous studies. Clinical information on previous surgeries could be a useful determinant of third liver resection for re-recurrent HCC.

References
1.
Toubert C, Guiu B, Al Taweel B, Assenat E, Panaro F, Souche F . Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!. Cancers (Basel). 2023; 15(1). PMC: 9818493. DOI: 10.3390/cancers15010232. View

2.
Nakajima Y, Ko S, Kanamura T, Nagao M, Kanehiro H, Hisanaga M . Repeat liver resection for hepatocellular carcinoma. J Am Coll Surg. 2001; 192(3):339-44. DOI: 10.1016/s1072-7515(00)00789-4. View

3.
Belghiti J, Panis Y, Farges O, Benhamou J, Fekete F . Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214(2):114-7. PMC: 1358509. DOI: 10.1097/00000658-199108000-00004. View

4.
Shin S, Ahn K, Kim S, Kim T, Kim Y, Kang K . Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systematic Review and Meta-analysis. Ann Surg. 2020; 273(4):656-666. DOI: 10.1097/SLA.0000000000004350. View

5.
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806-8. PMC: 2034723. DOI: 10.1136/bmj.39335.541782.AD. View